Nelivaptan
 | |
| IUPAC ime | |
|---|---|
(2S,4R)-1-[(3R)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxo-indolin-3-yl]-4-hydroxy-N,N-dimethyl-pyrrolidine-2-carboxamide | |
| Klinički podaci | |
| Način primene | Oralno |
| Identifikatori | |
| CAS broj | 439687-69-1 |
| PubChem | CID 9895468 |
| ChemSpider | 8071134 |
| Hemijski podaci | |
| Formula | C30H32ClN3O8S |
| Molarna masa | 630.11 g/mol |
Nelivaptan (INN[1]), kod SSR-149,415, je selektivni i oralno aktivni ne-peptidni antagonist vazopresinskog receptora koji je selektivan za V1b podtip.[2] Lek je bio u kliničkim ispitivanjima za tretman anksioznosti i depresija.[3] Jula 2008, Sanofi-Aventis je objavio da je dalji razvoj ovog leka obustavljen.[4]
Literatura[уреди | уреди извор]
- ^ World Health Organization (2007). „International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98” (PDF). WHO Drug Information. 21 (4): 341.
- ^ Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002). „Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders”. Proc. Natl. Acad. Sci. U.S.A. 99 (9): 6370—5. PMC 122955
. PMID 11959912. doi:10.1073/pnas.092012099.
- ^ Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A (2005). „An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders”. CNS drug reviews. 11 (1): 53—68. PMID 15867952. doi:10.1111/j.1527-3458.2005.tb00035.x.
- ^ „Second-quarter 2008 results” (PDF). Press Release. Sanofi-Aventis. 31. 07. 2008. Архивирано из оригинала (PDF) 06. 12. 2008. г. Приступљено 10. 06. 2009. „It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist).”
